Gene · 64006
Papers4,423
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 4,423
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. | Plasmonics | 2023 | 36588744 | PubTator, text mining | PubMed |
| The Spike protein of SARS-CoV-2 signals via Tlr2 in zebrafish. | Dev Comp Immunol | 2023 | 36587712 | PubTator, text mining | PubMed |
| Covid-19 and its relation to the human eye: transmission, infection, and ocular manifestations. | Graefes Arch Clin Exp Ophthalmol | 2023 | 36585987 | PubTator, text mining | PubMed |
| Emerging Landscape of SARS-CoV-2 Variants and Detection Technologies. | Mol Diagn Ther | 2023 | 36577887 | PubTator, text mining | PubMed |
| Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. | Proc Natl Acad Sci U S A | 2023 | 36574685 | PubTator, text mining | PubMed |
| Mpox diagnostics: Review of current and emerging technologies. | J Med Virol | 2023 | 36571266 | PubTator, text mining | PubMed |
| Network analysis of the autophagy biochemical network in relation to various autophagy-targeted proteins found among SARS-CoV-2 variants of concern. | J Mol Graph Model | 2023 | 36549224 | PubTator, text mining | PubMed |
| The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. | Nat Rev Immunol | 2023 | 36539527 | PubTator, text mining | PubMed |
| Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication. | Mol Biol Rep | 2023 | 36538171 | PubTator, text mining | PubMed |
| A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. | 3 Biotech | 2023 | 36532857 | PubTator, text mining | PubMed |
| Effect of COVID-19 on healthcare workers' morbidity and mortality compared to the general population in Kohgiluyeh and Boyer-Ahmad Province, Iran. | Health Sci Rep | 2023 | 36519077 | PubTator, text mining | PubMed |
| Cardiopulmonary and hematological effects of infrared LED photobiomodulation in the treatment of SARS-COV2. | J Photochem Photobiol B | 2023 | 36495670 | PubTator, text mining | PubMed |
| Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy. | Virus Res | 2023 | 36493993 | PubTator, text mining | PubMed |
| Host microRNAs exhibit differential propensity to interact with SARS-CoV-2 and variants of concern. | Biochim Biophys Acta Mol Basis Dis | 2023 | 36481486 | PubTator, text mining | PubMed |
| Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro. | Int J Biol Macromol | 2023 | 36481336 | PubTator, text mining | PubMed |
| SARS-CoV-2 Non-structural protein 1(NSP1) mutation virulence and natural selection: Evolutionary trends in the six continents. | Virus Res | 2023 | 36473671 | PubTator, text mining | PubMed |
| A comprehensive investigation of human endogenous retroviral syncytin proteins and their receptors in men with normozoospermia and impaired semen quality. | J Assist Reprod Genet | 2023 | 36469256 | PubTator, text mining | PubMed |
| Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences. | J Mol Struct | 2023 | 36467615 | PubTator, text mining | PubMed |
| Peptide microarray analysis of in-silico predicted B-cell epitopes in SARS-CoV-2 sero-positive healthcare workers in Bulawayo, Zimbabwe. | Acta Trop | 2023 | 36460093 | PubTator, text mining | PubMed |
| Quantification of SARS-CoV-2 in wastewater samples from hospitals treating COVID-19 patients during the first wave of the pandemic in Brazil. | Sci Total Environ | 2023 | 36436622 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64006/papers?page=32